Effects of Sodium-Glucose Cotransporter-2 Inhibitors and Thiazolidinedione on New-Onset Atrial Fibrillation Risk to Patients with Type 2 Diabetes.
Hae Geun SongYoo-Ri KimSeung Eun LeeHyewon NamHo-Seob KimDae-Sung KyoungKyoung-Ah KimPublished in: Reviews in cardiovascular medicine (2022)
In this study, the risk of new-onset AF is comparable in patients treated with SGLT-2i and TZD in T2D. Either SGLT-2i or TZD would be a reasonable choice for T2D patients who are at risk for AF.
Keyphrases
- atrial fibrillation
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- heart failure
- left atrial
- peritoneal dialysis
- prognostic factors
- catheter ablation
- direct oral anticoagulants
- percutaneous coronary intervention
- patient reported outcomes
- coronary artery disease
- venous thromboembolism